International Research Journal of Innovations in Engineering and Technology - IRJIET International Open Access, Monthly, Peer Reviewed, Reputed Journal ISSN (online): 2581-3048

Impact Factor (2025): 6.9

DOI Prefix: 10.47001/IRJIET

A Survey on Nanocontrast Agents for Cancer Diagnosis from MRI

Abstract

Contrast agents show its important function in spotting diseases from Magnetic resonance imaging (MRI) images. This will demand the development of novel MRI contrast agents which improves the sensitivity of an image. Although several contrast agents have been proposed for enhancing MRI images, nano- based contrast agent improves the image quality and increases diagnosing accuracy. T1-weighted contrast agents have the ability to enhance the intensity of the low-signal tissues where as T2-weighted Contrast agents have the ability to enhance the intensity of the images in high-signal tissues. This paper gives the overview about the involvement of nano-contrast agents in MRI images for cancer detection.

Country : India

1 Sabah Afroze A2 Tamilselvi R3 S M Seeni Mohamed Aliar Maraikkayar4 Parisa beham M

  1. Department of ECE, Sethu Institute of Technology, Virudhunagar, Tamilnadu, India
  2. Department of ECE, Sethu Institute of Technology, Virudhunagar, Tamilnadu, India
  3. Department of ECE, Sethu Institute of Technology, Virudhunagar, Tamilnadu, India
  4. Department of ECE, Sethu Institute of Technology, Virudhunagar, Tamilnadu, India

IRJIET, Volume 3, Issue 9, September 2019 pp. 12-16

Full Paper
Download

References

  1. Dornalds, “medical dictionary”, 32nd edition.
  2. Thomson, K; Varma, D (2010), "Safe use of radiographic contrast media". Australian Prescriber, 33:19-22. Available at Archived copy.
  3. Rinck P., “Magnetic Resonance in Medicine”, The Basic Textbook of the European Magnetic Resonance Forum, 11th edition; 2017.
  4. Brindle K, “New approaches for imaging tumor responses to treatment”, Nature Reviews Cancer, vol.8, pp.94–107 (2008).
  5. Weissleder R and Pittet MJ , “Imaging in the era of molecular oncology”, Nature, vol.452, pp.580–589 (2008).
  6. Caravan P, Ellison JJ, McMurry TJ and Lauffer RB, “Gadolinium (III) chelates as MRI contrast agents: Structure, dynamics, and applications”, Chemical Reviews, vol.99, pp.2293–2352 (1999).
  7. Lin WB, Hyeon T, Lanza GM, Zhang MQ, and Meade TJ, “Magnetic Nanoparticles for Early Detection of Cancer by Magnetic Resonance imaging”, Mrs. Bulletin, vol.34, pp.441–448 (2009).
  8. Villaraza AJL, Bumb A and Brechbiel MW, “Macromolecules, Dendrimers, and Nano materials in Magnetic Resonance Imaging: The Interplay between Size, Function, and Pharmacokinetics”, Chemical Reviews, vol.11, pp. 2921–2959 (2010).
  9. Luc Fauchera,b, Andre´e-Anne Guay-Be´gina,b, Jean Lagueuxa, Marie-France Coˆ te´ c, E´ ricPetitclercd and Marc-Andre´ Fortina,b, “Ultra-small gadolinium oxide nanoparticles to image brain cancer cells in vivo with MRI” , Contrast Media Mol. Imaging , John Wiley & Son Ltd, vol.6, pp.209–218, DOI:10.1002/cmmi.420 (2011).
  10. Yongjun Liu, Zhijin Chen, Chunxi Liu, Dexin Yu, Zaijun Lu and Na Zhang , “Gadolinium-loaded polymeric nanoparticles modified with Anti-VEGF as multifunctional MRI contrast agents for the diagnosis of liver cancer”, Biomaterials, Elsevier, vol.32, pp.5167-5176, doi:10.1016/j. biomaterials.2011.03.077 (2011).
  11. Taeho Kim, Eric Momin, Jonghoon Choi, Kristy Yuan, Hasan Zaidi, Jaeyun Kim, Mihyun Park, Nohyun Lee, Michael T. McMahon, Alfredo Quinones-Hinojosa, Jeff W. M. Bulte, Taeghwan Hyeon, and Assaf A. Gilad, “Mesoporous Silica-Coated Hollow Manganese Oxide Nanoparticles as Positive T1 Contrast Agents for Labeling and MRI Tracking of Adipose-Derived Mesenchymal Stem Cells”, J. Am.Chem. Soc, ACS publications, vol.133, pp.2955–2961, dx.doi.org/10.1021/ja1084095 (2011).
  12. Hyon Bin Na, Jung Hee Lee, Kwangjin An, Yong Il Park, Mihyun Park, In Su Lee, Do-Hyun Nam, Sung Tae Kim, Seung-Hoon Kim, Sang-Wook Kim, Keun-Ho Lim, Ki-Soo Kim, Sun-Ok Kim, and Taeghwan Hyeon, “Development of a T1 Contrast Agent for Magnetic Resonance Imaging Using MnO Nanoparticles”, Angew. Chem, vol.119, pp.5493–5497, DOI: 10.1002/ange.200604775 (2007).
  13. Wang YXJ, Hussain SM and Krestin GP, “Super paramagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging”, European Radiology, vol.11, pp.2319–2331 (2001).
  14. Enochs WS, Harsh G, Hochberg F, and Weissleder R, “Improved delineation of human brain tumors on MR images using a long-circulating, super paramagnetic iron oxide agent”, Journal of Magnetic Resonance Imaging, vol. 9, pp.228–232 (1999).
  15. Varallyay P, Nesbit G, Muldoon LL, Nixon RR, Delashaw J, Cohen JI, Petrillo A, Rink D and Neuwelt EA, “Comparison of two super paramagnetic viral-sized iron oxide particles ferumoxides andferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors”,  American Journal of Neuroradiology, vol.23, pp.510–519 (2002).
  16. Keshtkar M, Shahbazi-Gahrouei D, Mehrgardi M, Aghaei M and khoshfetrat S. M,  Synthesis and Cytotoxicity Assessment of Gold-coated Magnetic Iron Oxide Nanoparticles”, J Biomed Phys Eng, e-ISSN: 2251-7200 (2016).
  17. https://www.fda.gov/Drugs/DrugSafety/Postmarket Drug Safety Information for Patients and Providers/ucm142882.html.

Copyright @ 2026-2017 IRJIET. All Right Reserved.

Developed by Byzero Technologies